No Data
Soleno Therapeutics Reports Q3 Progress and Financials
Express News | Soleno Therapeutics Announces Oral Presentations Featuring Diazoxide Choline Extended-Release (Dccr) Tablets in Prader-Willi Syndrome at Espe 2024
H.C. Wainwright Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $70
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74